PT - JOURNAL ARTICLE AU - Márquez-Ipiña, Alan Roberto AU - González-González, Everardo AU - Rodríguez-Sánchez, Iram Pablo AU - Lara-Mayorga, Itzel Montserrat AU - Mejía-Manzano, Luis Alberto AU - González-Valdez, José AU - Ortiz-Lopez, Rocio AU - Rojas-Martinez, Augusto AU - Santiago, Grissel Trujillo-de AU - Moisés Alvarez, Mario TI - Cost-effective serological test to determine exposure to SARS-CoV-2: ELISA based on the receptor-binding domain of the spike protein (Spike-RBD<sub>N318-V510</sub>) expressed in <em>Escherichia coli</em> AID - 10.1101/2020.09.15.20195503 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.15.20195503 4099 - http://medrxiv.org/content/early/2020/09/18/2020.09.15.20195503.short 4100 - http://medrxiv.org/content/early/2020/09/18/2020.09.15.20195503.full AB - Massive worldwide serological testing for SARS-CoV-2 is needed to determine the extent of virus exposure in a particular region, the ratio of symptomatic to asymptomatic infected persons, and the duration and extent of immunity after infection. To achieve this aim, the development and production of reliable and cost-effective SARS-CoV-2 antigens is critical.Here, we report the bacterial production of the peptide S-RBDN318-V510, which contains the receptor binding domain of the SARS-CoV-2 spike protein. We purified this peptide using a straightforward approach involving bacterial lysis, his-tag mediated affinity chromatography, and imidazole-assisted refolding. The antigen performances of S-RBDN318-V510 and a commercial full-length spike protein were compared in two distinct ELISAs. In direct ELISAs, where the antigen was directly bound to the ELISA surface, both antigens discriminated sera from non-exposed and exposed individuals. However, the discriminating resolution was better in ELISAs that used the full-spike antigen than the S-RBDN318-V510. Attachment of the antigens to the ELISA surface using a layer of anti-histidine antibodies gave equivalent resolution for both S-RBDN318-V510 and the full length spike protein.Our results demonstrate that ELISA-functional SARS-CoV-2 antigens can be produced in bacterial cultures. S-RBDN318-V510 is amenable to massive production and may represent a cost-effective alternative to the use of structurally more complex antigens in serological COVID-19 testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors aknowledge the funding provided by the Federico Baur Endowed Chair in Nanotechnology (0020240I03). EGG acknowledges funding from a doctoral scholarship provided by CONACyT (Consejo Nacional de Ciencia y Tecnologia, Mexico). GTdS and MMA acknowledge the institutional funding received from Tecnologico de Monterrey (Grant 002EICIS01). MMA, GTdS, and IMLM acknowledge funding provided by CONACyT (Consejo Nacional de Ciencia y Tecnologia, Mexico) through grants SNI 26048, SNI 256730, and SNI 1056909, respectively.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The experimental protocol was approved on May 20th, 2020 by a named institutional committee (Alfa Medical Center, Research Comitte; resolution AMCCI-TECCOVID-001). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data related to this manuscript is contain within.